

Whitney B Pope

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9480834/whitney-b-pope-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

161
papers

8,232
citations

49
h-index

88
g-index

167
ext. papers

9,492
ext. citations

4.4
avg, IF

5.87
L-index

#	Paper	IF	Citations
161	Radiomics for precision medicine in glioblastoma.. <i>Journal of Neuro-Oncology</i> , 2022 , 156, 217	4.8	3
160	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.. <i>Scientific Reports</i> , 2022 , 12, 1078	4.9	1
159	Imaging Advances for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 43-61	3.1	0
158	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.. <i>Frontiers in Oncology</i> , 2022 , 12, 849993	5.3	
157	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022 , 14, 2520	6.6	0
156	Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. <i>Tomography</i> , 2022 , 8, 1437-1452	3.1	
155	NIMG-74. RESPONSE ASSESSMENT AFTER DOSE-ESCALATED RADIOTHERAPY: IMAGING PROTOCOL OF A MULTICENTER PHASE III TRIAL ON INTRAOPERATIVE RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA (INTRAGO-II;ARO2016-1;AG-NRO-03). <i>Neuro-Oncology</i> , 2021 , 23, vi146-vi146	1	
154	NIMG-41. PH-WEIGHTED MOLECULAR MRI AS AN EARLY BIOMARKER OF METABOLIC RESPONSE TO IDH INHIBITION IN IDH MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2021 , 23, vi138-vi138	1	
153	"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging.. <i>NeuroImage: Clinical</i> , 2021 , 32, 102882	5.3	0
152	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021 , 21, 27	5.6	4
151	Using non-invasive neuroimaging to enhance the care, well-being and experimental outcomes of laboratory non-human primates (monkeys). <i>NeuroImage</i> , 2021 , 228, 117667	7.9	8
150	Preferential tumor localization in relation to F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021 , 152, 573-582	4.8	1
149	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021 , 35, 1022-1029	2.5	1
148	Voxelwise and Patientwise Correlation of F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021 , 62, 319-325	8.9	9
147	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021 , 63, 857-868	3.2	4
146	Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). <i>Brain Imaging and Behavior</i> , 2021 , 1	4.1	1
145	NIMG-36. VISUALIZATION OF TUMOR HETEROGENEITY AND PREDICTION OF ISOCITRATE DEHYDROGENASE MUTATION STATUS FOR HUMAN GLIOMAS BY USING MULTIPARAMETRIC PHYSIOLOGIC AND METABOLIC MRI. <i>Neuro-Oncology</i> , 2021 , 23, vi136-vi137	1	

144	NIMG-44. PROGNOSTIC VALUE OF PH- AND OXYGEN-SENSITIVE MRI IN GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2021 , 23, vi138-vi139	1	
143	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020 , 87, 931-938	3.2	2
142	The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China. <i>Frontiers in Oncology</i> , 2020 , 10, 852	5.3	3
141	Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 643-652	4.8	3
140	Rate of change in maximum F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020 , 147, 135-145	4.8	9
139	Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. <i>iScience</i> , 2020 , 23, 101453	6.1	22
138	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020 , 10, 11922	4.9	12
137	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 337-346	4.8	4
136	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020 , 10, 14819	4.9	3
135	Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy. <i>Journal of Neuroradiology</i> , 2020 , 47, 166-173	3.1	1
134	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020 , 22, 17-30	1	43
133	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019 , 40, 979-986	4.4	14
132	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019 , 21, 1184-1196	1	15
131	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019 , 9, 2846	4.9	17
130	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019 , 21, 837-853	1	37
129	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 142, 587-595	4.8	15
128	PET imaging in patients with brain metastasis-report of the RANO/PET group. <i>Neuro-Oncology</i> , 2019 , 21, 585-595	1	72
127	F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 399-409	4.8	28

126	Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. <i>Neuro-Oncology</i> , 2018 , 20, 1525-1535	1	12
125	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 1240-1250	1	39
124	Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). <i>Magnetic Resonance in Medicine</i> , 2018 , 80, 1962-1978	4.4	30
123	Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging. <i>American Journal of Neuroradiology</i> , 2018 , 39, 43-45	4.4	10
122	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 1195-1203	4	29
121	Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of four doses of the macrocyclic agent gadobutrol. <i>European Radiology</i> , 2018 , 28, 4882-4889	8	11
120	Gadolinium Deposition within the Pediatric Brain: No Increased Intrinsic T1-Weighted Signal Intensity within the Dentate Nucleus following the Administration of a Minimum of 4 Doses of the Macrocyclic Agent Gadoteridol. <i>American Journal of Neuroradiology</i> , 2018 , 39, 1604-1608	4.4	12
119	Brain metastases: neuroimaging. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018 , 149, 89-112	3	76
118	Improving B Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. <i>Tomography</i> , 2018 , 4, 123-137	3.1	12
117	Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 62, 239-253	1.4	37
116	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 651-659	4.8	18
115	Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 228-234	2.7	60
114	The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. <i>NeuroImage: Clinical</i> , 2017 , 13, 386-394	5.3	76
113	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017 , 134, 177-188	4.8	83
112	Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. <i>Journal of Neuro-Oncology</i> , 2017 , 134, 495-504	4.8	95
111	Evaluation of Magnetanoparticles Conjugated with New Angiogenesis Peptides in Intracranial Glioma Tumors by MRI. <i>Applied Biochemistry and Biotechnology</i> , 2017 , 183, 265-279	3.2	5
110	Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas. <i>European Journal of Radiology</i> , 2017 , 97, 31-36	4.7	27
109	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017 , 23, 5745-5756	12.9	44

108	Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis?. <i>Neuropathology</i> , 2017 , 37, 233-240	2	13
107	Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. <i>Neuro-Oncology</i> , 2017 , 19, 89-98	1	48
106	Molecular Imaging of Diffuse Low Grade Glioma 2017 , 173-195		
105	Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 467-78	1	51
104	Between-Scanner and Between-Visit Variation in Normal White Matter Apparent Diffusion Coefficient Values in the Setting of a Multi-Center Clinical Trial. <i>Clinical Neuroradiology</i> , 2016 , 26, 423-430	27	15
103	Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016 , 24, 649-670	1.6	32
102	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. <i>NMR in Biomedicine</i> , 2016 , 29, 1563-1576	4.4	40
101	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. <i>Cancer</i> , 2016 , 122, 1718-27	6.4	37
100	Blood-Labyrinth Barrier Permeability in Menière Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1903-1908	4.4	49
99	Neuroimaging. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 27-50	3	6
98	Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. <i>Journal of Magnetic Resonance Imaging</i> , 2016 , 44, 1229-1237	5.6	25
97	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016 , 22, 575-81	12.9	47
96	Modeling the efficacy of the extent of surgical resection in the setting of radiation therapy for glioblastoma. <i>Cancer Science</i> , 2016 , 107, 1110-6	6.9	13
95	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1440-6	4.4	26
94	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1199-208	1	398
93	Two cases of rheumatoid meningitis. <i>Neuropathology</i> , 2016 , 36, 93-102	2	30
92	Nitroxoline induces apoptosis and slows glioma growth in vivo. <i>Neuro-Oncology</i> , 2015 , 17, 53-62	1	34
91	From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?. <i>Neuro-Oncology</i> , 2015 , 17, 1434-44	1	116

90	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 497-505	4.8	31
89	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015 , 17, 434-42	3.8	27
88	Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. <i>Clinical Cancer Research</i> , 2015 , 21, 4373-83	12.9	18
87	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , <i>The</i> , 2015 , 16, e534-e542	21.7	425
86	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. <i>Neuro-Oncology</i> , 2015 , 17, 1514-24	1	73
85	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015 , 17, 1188-98	1	224
84	Standardized Brain Tumor Imaging Protocol for Clinical Trials. <i>American Journal of Neuroradiology</i> , 2015 , 36, E65-6	4.4	2
83	Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. <i>CNS Oncology</i> , 2015 , 4, 247-56	4	13
82	Genomics of brain tumor imaging. <i>Neuroimaging Clinics of North America</i> , 2015 , 25, 105-19	3	28
81	Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. <i>NeuroImage: Clinical</i> , 2015 , 9, 617-24	5.3	14
80	NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI). <i>Neuro-Oncology</i> , 2015 , 17, v158.4-v159	1	50
79	Evidence for rCBV as an early response marker following bevacizumab treatment. <i>Neuro-Oncology</i> , 2015 , 17, 1539-40	1	2
78	A novel bicompartamental mathematical model of glioblastoma multiforme. <i>International Journal of Oncology</i> , 2015 , 46, 825-32	4.4	5
77	Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. <i>Oncology Reports</i> , 2015 , 33, 2883-8	3.5	5
76	Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. <i>Tomography</i> , 2015 , 1, 37-43	3.1	9
75	C-terminally truncated form of B-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014 , 117, 53-65	4.8	7
74	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014 , 116, 551-8	4.8	9
73	Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Journal of Neuro-Oncology</i> , 2014 , 116, 601-8	4.8	6

72	Intraoperative mass spectrometry of tumor metabolites. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 10906-7	11.5	2
71	Isolated choroid plexus granulomas: initial presentation of neurosarcoidosis?. <i>Canadian Journal of Neurological Sciences</i> , 2014 , 41, 112-4	1	
70	Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. <i>Neuro-Oncology</i> , 2014 , 16, 414-20	1	60
69	Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. <i>Cancer Imaging</i> , 2014 , 14, 31	5.6	19
68	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii36-47	1	38
67	Emerging techniques and technologies in brain tumor imaging. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii12-23		33
66	BI-10pH-WEIGHTED MRI IN HUMAN GLIOMAS. <i>Neuro-Oncology</i> , 2014 , 16, v25-v25	1	78
65	Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. <i>Radiology</i> , 2014 , 271, 200-10	20.5	121
64	Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3550-9	12.9	97
63	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014 , 16, 815-22	1	41
62	Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. <i>Journal of Neuroimaging</i> , 2014 , 24, 23-30	2.8	38
61	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. <i>Journal of Neuro-Oncology</i> , 2014 , 116, 373-9	4.8	73
60	Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2007-2007	2.2	3
59	Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013 , 112, 257-66	4.8	11
58	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. <i>CNS Oncology</i> , 2013 , 2, 33-47	4	16
57	Ensemble segmentation for GBM brain tumors on MR images using confidence-based averaging. <i>Medical Physics</i> , 2013 , 40, 093502	4.4	10
56	Primary central nervous system histiocytic sarcoma presenting as a postradiation sarcoma: case report and literature review. <i>Human Pathology</i> , 2013 , 44, 1177-83	3.7	28
55	PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. <i>PET Clinics</i> , 2013 , 8, 201-17	2.2	5

54	Magnetic Resonance Imaging of Glioma in the Era of Antiangiogenic Therapy. <i>PET Clinics</i> , 2013 , 8, 163-82.2		4
53	Multi-delay multi-parametric arterial spin-labeled perfusion MRI in acute ischemic stroke - Comparison with dynamic susceptibility contrast enhanced perfusion imaging. <i>NeuroImage: Clinical</i> , 2013 , 3, 1-7	5.3	128
52	Functionalized magnetonanoparticles in visualization of intracranial tumors on MRI. <i>Molecular Imaging and Biology</i> , 2013 , 15, 299-306	3.8	4
51	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. <i>Neuro-Oncology</i> , 2013 , 15, 370-81	1	81
50	Brainstem Gliomas 2013 , 18, 237-242		
49	Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. <i>Neuro-Oncology</i> , 2013 , 15, 626-34	1	78
48	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Neuro-Oncology</i> , 2013 , 15, 382-90	1	36
47	Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. <i>Magnetic Resonance in Medicine</i> , 2012 , 67, 237-45	4.4	34
46	Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 111-9	4.8	56
45	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. <i>Journal of Neuro-Oncology</i> , 2012 , 107, 197-205	4.8	237
44	Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. <i>NeuroImage</i> , 2012 , 59, 908-16	7.9	97
43	Current concepts in brain tumor imaging. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 119-24	7.1	1
42	Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. <i>Journal of Magnetic Resonance Imaging</i> , 2012 , 35, 1472-7	5.6	55
41	Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 491-8	4.8	134
40	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2012 , 14, 333-43 ¹		69
39	³ Qdeoxy- ³ Q ¹ 8F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 29-36	8.9	110
38	The value of arterial spin-labeled perfusion imaging in acute ischemic stroke: comparison with dynamic susceptibility contrast-enhanced MRI. <i>Stroke</i> , 2012 , 43, 1018-24	6.7	121
37	¹⁸ F-FDOPA and ¹⁸ F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. <i>Neuro-Oncology</i> , 2012 , 14, 1079-89 ¹	1	84

36	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. <i>Neuro-Oncology</i> , 2012 , 14, 1465-72	1	33
35	Sampling-based ensemble segmentation against inter-operator variability 2011 ,		2
34	Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2011 , 105, 91-101	4.8	32
33	Advances in MRI assessment of gliomas and response to anti-VEGF therapy. <i>Current Neurology and Neuroscience Reports</i> , 2011 , 11, 336-44	6.6	89
32	High order diffusion tensor imaging in human glioblastoma. <i>Academic Radiology</i> , 2011 , 18, 947-54	4.3	8
31	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4482-90	2.2	337
30	Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011 , 13, 401-9	1	81
29	Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. <i>Neuro-Oncology</i> , 2011 , 13, 1151-61	1	61
28	Confidence-based ensemble for GBM brain tumor segmentation 2011 ,		1
27	Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. <i>Journal of Clinical Oncology</i> , 2011 , 29, 142-8	2.2	358
26	Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. <i>Pharmacogenomics and Personalized Medicine</i> , 2010 , 3, 79-85	2.1	4
25	Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's disease. <i>Journal of Neurology</i> , 2010 , 257, 839-42	5.5	10
24	Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. <i>Journal of Neuro-Oncology</i> , 2010 , 96, 359-67	4.8	72
23	CADrx for GBM Brain Tumors: Predicting Treatment Response from Changes in Diffusion-Weighted MRI. <i>Algorithms</i> , 2009 , 2, 1350-1367	1.8	6
22	Engagement of fusiform cortex and disengagement of lateral occipital cortex in the acquisition of radiological expertise. <i>Cerebral Cortex</i> , 2009 , 19, 2746-54	5.1	76
21	Histogram-based classification with Gaussian mixture modeling for GBM tumor treatment response using ADC map 2009 ,		3
20	Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. <i>Radiology</i> , 2009 , 252, 182-9	20.5	271
19	¹⁸ F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. <i>European Journal of Radiology</i> , 2009 , 71, 242-8	4.7	87

18	Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. <i>Human Pathology</i> , 2009 , 40, 1200-4	3.7	5
17	Activity in the fusiform face area supports expert perception in radiologists and does not depend upon holistic processing of images 2009 ,		1
16	A methodology to integrate clinical data for the efficient assessment of brain-tumor patients. <i>Informatics for Health and Social Care</i> , 2008 , 33, 55-68	2.7	4
15	Safety of anticoagulation use and bevacizumab in patients with glioma. <i>Neuro-Oncology</i> , 2008 , 10, 355-60		71
14	Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. <i>Radiology</i> , 2008 , 249, 268-77	20.5	133
13	3-T contrast-enhanced MR angiography in evaluation of suspected intracranial aneurysm: comparison with MDCT angiography. <i>American Journal of Roentgenology</i> , 2008 , 190, 389-95	5.4	30
12	Time course of imaging changes of GBM during extended bevacizumab treatment. <i>Journal of Neuro-Oncology</i> , 2008 , 88, 339-47	4.8	96
11	Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1372-80	4	151
10	Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. <i>Clinical Cancer Research</i> , 2007 , 13, 2592-8	12.9	92
9	Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4714-21	2.2	352
8	Supraaortic arteries: contrast-enhanced MR angiography at 3.0 T--highly accelerated parallel acquisition for improved spatial resolution over an extended field of view. <i>Radiology</i> , 2007 , 242, 600-9	20.5	50
7	High spatial-resolution CE-MRA of the carotid circulation with parallel imaging: comparison of image quality between 2 different acceleration factors at 3.0 Tesla. <i>Investigative Radiology</i> , 2006 , 41, 391-9	10.1	47
6	Contrast-enhanced MR angiography at 3T in the evaluation of intracranial aneurysms: a comparison with time-of-flight MR angiography. <i>American Journal of Neuroradiology</i> , 2006 , 27, 2118-21	4.4	38
5	18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 904-11	8.9	264
4	MR imaging correlates of survival in patients with high-grade gliomas. <i>American Journal of Neuroradiology</i> , 2005 , 26, 2466-74	4.4	291
3	Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. <i>Experimental Neurology</i> , 1994 , 126, 185-94	5.7	82
2	Phosphorylated tau epitope of Alzheimer's disease is coupled to axon development in the avian central nervous system. <i>Experimental Neurology</i> , 1993 , 120, 106-13	5.7	38
1	Transient expression of adhesion molecules during chick retinal development. <i>Journal of Neurobiology</i> , 1992 , 23, 720-38		2

